Abstract
Platinum-based anticancer drugs enhance the immunostimulatory potential of DCs and decrease the immunosuppressive capacity of tumor cells. This immunomodulatory ability is based on the inhibition of STAT6-mediated expression of co-inhibitory molecule PD-L2 and opens up the possibility of using these drugs in combination with other immunostimulatory compounds. © 2012 Landes Bioscience.
Author supplied keywords
Cite
CITATION STYLE
APA
Hato, S. V., de Vries, I. J. M., & Lesterhuis, W. J. (2012). STATing the importance of immune modulation by platinum chemotherapeutics. OncoImmunology. https://doi.org/10.4161/onci.1.2.18126
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free